Sobi
Sobi Acquires Arthrosi Therapeutics for $950M Upfront in Gout Drug Deal
Sobi; Arthrosi Therapeutics; acquisition; gout; pozdeutinurad; AR882
Apellis and Sobi Achieve Significant Breakthrough in Phase 3 Trial for Rare Kidney Disease Treatment
Apellis Pharmaceuticals, Sobi, pegcetacoplan, Phase 3 VALIANT study, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, proteinuria reduction, kidney disease treatment, FDA approval, European Medicines Agency